The safety of daclatasvir for the treatment of hepatitis C
Jafri SM, and Gordon SC. The safety of daclatasvir for the treatment of hepatitis C. Expert Opin Drug Saf 2015; 14(11):1787-1797.
Expert opinion on drug safety
INTRODUCTION: The direct acting antiviral daclatasvir is an NS5A replication inhibitor active against the entire range of hepatitis C virus genotypes. It is a key step in establishing the goal of an all-oral, ribavirin-free, pan-genotypic regimen against hepatitis C.
AREAS COVERED: We review current literature including published abstracts and manuscripts. Evidence was obtained through PubMed/Medline search using listed keywords and through review of published abstracts.
EXPERT OPINION: Daclatasvir introduces a degree of pangenotypic potency currently lacking in other NS5A agents. Emerging literature suggests that daclatasvir in combination with other DAAs will represent a promising option in this difficult to treat populations including posttransplant, genotype 3 and HIV patients.
Medical Subject Headings
Administration, Oral; Animals; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Virus Replication